Ionis Pharmaceuticals

Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs
Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs
Fierce Biotech
Roche
Ionis Pharmaceuticals
RNA
Alzheimer's disease
Huntington's disease
Flag link:
Ionis Notches Phase III Win in Rare Genetic Disease, Plans to Submit NDA
Ionis Notches Phase III Win in Rare Genetic Disease, Plans to Submit NDA
BioSpace
Ionis Pharmaceuticals
antisense
olezarsen
Flag link:
Ionis' lipid-lowering drug hits phase 3 goal, raising hopes in untapped rare disease market
Ionis' lipid-lowering drug hits phase 3 goal, raising hopes in untapped rare disease market
Fierce Biotech
Ionis Pharmaceuticals
clinical trials
olezarsen
familial chylomicronemia syndrome
Flag link:
Spotlight – Nash in 2023 and beyond
Spotlight – Nash in 2023 and beyond
EP Vantage
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Flag link:
AstraZeneca adds Latin America to Ionis ATTR partnership for $20M
AstraZeneca adds Latin America to Ionis ATTR partnership for $20M
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
Latin American
eplontersen
ATTR
Flag link:
Roche drops antisense drug after seeing efficacy data, leaving Biogen, Ionis and Ultragenyx to duke it out
Roche drops antisense drug after seeing efficacy data, leaving Biogen, Ionis and Ultragenyx to duke it out
Fierce Biotech
Roche
Angelman Syndrome
antisense
Biogen
Ionis Pharmaceuticals
Ultragenyx
rugonersen
Flag link:
FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
Medical Marketing and Media
Biogen
Ionis Pharmaceuticals
ALS
tofersen
FDA
Flag link:
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Fierce Biotech
Ionis Pharmaceuticals
AstraZeneca
eplontersen
Alnylam
ATTR
Flag link:
Could This Rare-Disease Drug Candidate Become a Blockbuster?
Could This Rare-Disease Drug Candidate Become a Blockbuster?
Motley Fool
AstraZeneca
Ionis Pharmaceuticals
eplontersen
ATTR amyloidosis
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
aplontersen
Alnylam
Onpattro
clinical trials
ATTRv-PN
Flag link:
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Investors Business Daily
Ionis Pharmaceuticals
Biogen
ALS
FDA
tofersen
Flag link:
Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm
Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm
BioSpace
ALS
Biogen
Ionis Pharmaceuticals
FDA
tofersen
clinical trials
Flag link:
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy
PR Newswire
Ionis Pharmaceuticals
FDA
eplontersen
hATTR-pn
Flag link:
Go or no go? Vaccines and neurology up for discussion
Go or no go? Vaccines and neurology up for discussion
EP Vantage
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Flag link:
Biogen/ Ionis ALS therapy set for March FDA AdCom meeting
Biogen/ Ionis ALS therapy set for March FDA AdCom meeting
Seeking Alpha
Biogen
Ionis Pharmaceuticals
FDA
ALS
tofersen
Flag link:
JPM23: Ionis CEO admits PCSK9 ship captained by Big Pharmas may have sailed
JPM23: Ionis CEO admits PCSK9 ship captained by Big Pharmas may have sailed
Fierce Biotech
Ionis Pharmaceuticals
AstraZeneca
ION449
Flag link:
Ionis gets into gene editing
Ionis gets into gene editing
EP Vantage
Ionis Pharmaceuticals
gene editing
Metagenomi
Flag link:
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Yahoo Finance
Ionis Pharmaceuticals
clinical trials
donidalorsen
hereditary angiodema
HAE
Flag link:
As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data
As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data
Endpoints
Roche
Ionis Pharmaceuticals
IONIS-FB-LRx
kidney disease
Flag link:

Pages